上皮成長因子受容体（EGFR）遺伝子変異陽性非小細胞肺癌（NSCLC）患者の治療実態に関する調査

基本情報

NCT ID

NCT02475720

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

2,000

治験依頼者名

AstraZeneca

概要

According to the recent report using EGFR tyrosine kinase inhibitors (EGFR-TKI), there is all over survival of the EGFR gene mutation-positive NSCLC in a tendency to extension. However, the real situation and the reason are not clarified.This observational study collects the data of EGFR gene mutation-positive NSCLC approximately 2,000 from the medical record of approximately 20 facilities in Japan and observes the treatment reality of EGFR gene mutation-positive NSCLC.

対象疾患

依頼者（Sponsor）

実施施設 (1)